论文部分内容阅读
目的观察131I-抗hnRNPB1单克隆抗体(131I-抗hnRNPB1 MAb)、抗hnRNPB1 MAb对肺癌小鼠移植瘤的靶向治疗作用。方法用常规氯胺-T法合成131I-抗hnRNPB1 MAb,30只C57BL/6小鼠皮下接种Lewis肺癌细胞7 d后,将荷瘤鼠随机分成5组,每组6只。分别经尾静脉注射,组:131I-抗hnRNPB1 MAb 11.1 MBq/鼠单次治疗,组:131I-抗hnRNPB1 MAb 11.1 MBq/鼠强化治疗(给药2次,每次给药间隔3 d),组:Na131I 11.1MBq/鼠,组:抗hnRNPB1 MAb 50μg/鼠,组(对照组):生理盐水0.12 mL/鼠。治疗开始后每周测量1次小鼠肿瘤的长径及短径,4周后处死小鼠,分离肿瘤并称其质量,计算抑瘤率,肿瘤组织作常规HE染色检查。结果治疗结束时,、、、、组小鼠的平均肿瘤体积分别为(3869±192)mm3、(1987±149)mm3、(6922±532)mm3、(6962±509)mm3、(6597±521)mm3,其中、组分别与对照组相比差异具有统计学意义(P<0.05),且组的平均肿瘤体积小于组(P<0.05),而、组治疗结束时平均肿瘤体积分别与对照组相比差异无统计学意义。、组的抑瘤率分别为67.17%和39.03%,高于(1.36%)、(0.9%)组的抑瘤率(P<0.05),且、组间抑瘤率的差异亦有统计学意义(P<0.05)。结论抗hnRNPB1 MAb结合131I对肺癌小鼠移植瘤的生长具有明显抑制作用,且抑制作用呈量效关系。
Objective To observe the targeted therapeutic effects of 131I-anti-hnRNPB1 monoclonal antibody (131I-anti-hnRNPB1 MAb) and anti-hnRNPB1 MAb on lung cancer xenografts in mice. Methods 131I-anti-hnRNPB1 MAbs were synthesized by conventional chloramine-T method. 30 Lewis lung cancer cells were subcutaneously inoculated into C57BL/6 mice. After 7 days, the mice were randomly divided into 5 groups with 6 mice in each group. Injected via the tail vein respectively, group: 131I-anti-hnRNPB1 MAb 11.1 MBq/mouse single treatment, group: 131I-anti-hnRNPB1 MAb 11.1 MBq/mouse intensive treatment (administration 2 times, interval 3 days), group : Na131I 11.1 MBq/mouse, group: anti-hnRNPB1 MAb 50 μg/mouse, group (control): normal saline 0.12 mL/rat. After the beginning of treatment, the length and length of the tumor were measured once a week. After 4 weeks, the mice were sacrificed. The tumors were isolated and their mass was determined. The tumor inhibition rate was calculated and the tumor tissues were examined by routine HE staining. Results At the end of treatment, the average tumor volume of the mice in the groups was (3869±192) mm3, (1987±149) mm3, (6922±532) mm3, (6962±509) mm3, (6597±521). ) mm3, where the difference between the group and the control group was statistically significant (P<0.05), and the average tumor volume of the group was smaller than the group (P<0.05), and the average tumor volume at the end of the treatment group was compared with that of the control group. The difference was not statistically significant. The tumor inhibition rates of the group and the group were 67.17% and 39.03%, respectively, higher than the tumor inhibition rates of the (1.36%) and (0.9%) groups (P<0.05). Also, the difference in tumor inhibition rates between the groups was statistically significant. (P<0.05). Conclusion The anti-hnRNPB1 MAb combined with 131I can significantly inhibit the growth of transplanted tumors in lung cancer mice, and the inhibitory effect was dose-effect relationship.